Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Liraglutide

These articles are all highly relevant Liraglutide. I believe this information can help you understand Liraglutide's professional information. If you want to know more, you can contact us at any time, we can provide you with more professional guidance.
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 18 2024

    Drug Patent & Exclusivity Expiration Report - Week of Nov 18 2024

    2024-11-18

    This week, there are 8 drugs in the patent and exclusivity list. They are: - KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE - NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE - NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE - BRISTOL MYERS SQUIBB's REVLIMID, containing active ingredient LENALIDOMIDE - CUMBERLAND PHARMACEUTICALS INC's CALDOLOR, containing active ingredient IBUPROFEN - AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE - ALNYLAM PHARMACEUTICALS INC's GIVLAARI, containing active ingredient GIVOSIRAN SODIUM - AADI BIOSCIENCE INC's FYARRO, containing active ingredient SIROLIMUS Read More